Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN vs DARVON W/ ASA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Combination analgesic: propoxyphene is a weak opioid agonist binding to mu-opioid receptors, inhibiting ascending pain pathways; aspirin irreversibly inhibits cyclooxygenase-1 and -2, reducing prostaglandin synthesis.
Mild to moderate pain,Cough suppression (off-label)
Mild to moderate pain,Pain accompanied by inflammation or fever
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
1 capsule (propoxyphene HCl 65 mg / aspirin 650 mg) orally every 4 hours as needed for pain, not to exceed 6 capsules per day.
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Propoxyphene terminal half-life is 6–12 hours (mean 8 h) in healthy adults; prolonged in hepatic impairment or elderly due to reduced metabolism. Aspirin half-life is 15–20 minutes due to rapid hydrolysis to salicylate.
Not recommended in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min), reduce frequency to every 6-8 hours; use with caution.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²). For moderate impairment (e GFR 30-59), reduce dose to 1 capsule every 6 hours. No adjustment needed for mild impairment (e GFR ≥60).
Risk of respiratory depression, addiction, abuse, and misuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Propoxyphene is contraindicated in pregnancy due to risk of neonatal opioid withdrawal syndrome and respiratory depression. Acetaminophen is generally considered safe in pregnancy at therapeutic doses. First trimester: Propoxyphene may increase risk of congenital malformations, though data are limited. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal; high doses near term may cause respiratory depression in the neonate.
First trimester: Aspirin component associated with increased risk of neural tube defects and gastroschisis. Propoxyphene not associated with major malformations but data limited. Second trimester: Aspirin risk increases for fetal intracranial hemorrhage with chronic use. Third trimester: Aspirin may cause premature closure of ductus arteriosus, oligohydramnios, and increased perinatal hemorrhage. Propoxyphene may cause neonatal withdrawal syndrome.
Propoxyphene is a weak opioid with a narrow therapeutic index; acetaminophen component limits daily dose due to hepatotoxicity risk. Propoxyphene has been withdrawn in many countries due to cardiotoxicity (QT prolongation, arrhythmias) and overdose risks. Avoid in elderly due to accumulation of norpropoxyphene metabolite. Use with caution in renal impairment. Monitor for CNS depression when combined with other depressants.
Darvon with ASA contains propoxyphene and aspirin. Propoxyphene has been withdrawn from the US market due to cardiotoxicity (QT prolongation, risk of fatal arrhythmias). Use is not recommended; consider alternatives. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Avoid in children with viral illness due to Reye's syndrome risk.
No interactions on record
No interactions on record
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN and DARVON W/ ASA are distinct pharmacological agents. PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN belongs to the Opioid Analgesic Combination class and is primarily used for Mild to moderate painCough suppression (off-label). DARVON W/ ASA belongs to the Opioid Analgesic Combination class and is primarily used for Mild to moderate painPain accompanied by inflammation or fever. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN carries a safety status of Category C, whereas DARVON W/ ASA safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Propoxyphene: hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active); acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1.
Propoxyphene undergoes hepatic metabolism via N-demethylation to norpropoxyphene (active metabolite); both are primarily excreted renally. Aspirin is rapidly hydrolyzed to salicylate, which is metabolized by conjugation and oxidation, with renal excretion.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Renal elimination of propoxyphene and its metabolites accounts for ~70% of a dose, with ~20% excreted unchanged in urine; biliary/fecal elimination accounts for ~10%; aspirin is renally excreted as salicylate and its conjugates.
Propoxyphene: ~80% bound to albumin; Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Propoxyphene is 70–80% bound to albumin; aspirin is 50–80% bound to albumin (dose-dependent due to saturable binding).
Propoxyphene: 12-26 L/kg (large, extensive tissue distribution; clinical meaning: high CNS penetration). Acetaminophen: 0.9-1.0 L/kg (clinical meaning: uniform distribution, limited tissue binding).
Propoxyphene Vd is 6–10 L/kg, indicating extensive tissue distribution; aspirin Vd is 0.15–0.2 L/kg, primarily in plasma and extracellular fluid.
Oral: Propoxyphene ~30-70% due to extensive first-pass metabolism; Acetaminophen ~85-90%.
Propoxyphene: 30–70% oral bioavailability due to first-pass metabolism; aspirin: 50–70% oral bioavailability (first-pass hydrolysis to salicylate).
Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh A or B, reduce dose by 50% and monitor hepatic function; maximum duration limited.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, maximum 2 capsules per day. For Child-Pugh class A, no adjustment required but monitor closely.
Not recommended for pediatric use due to risk of respiratory depression and propoxyphene toxicity; safety and efficacy not established.
Not recommended for children under 12 years. For children 12-18 years: 1 capsule (propoxyphene 65 mg/aspirin 650 mg) every 4 hours as needed, maximum 6 capsules/day. Weight-based dosing not established due to fixed combination.
Initiate with lower doses (e.g., half tablet) and increase cautiously; avoid in elderly with renal or hepatic impairment; monitor for CNS and respiratory effects.
Initiate with 1 capsule every 6 hours. Maximum 4 capsules per day due to increased sensitivity and risk of CNS depression and renal impairment. Avoid in patients >75 years or those with frailty.
Propoxyphene is associated with a risk of fatal respiratory depression, especially in overdose or when combined with CNS depressants. Use with caution in elderly, debilitated, or patients with respiratory compromise.
Risk of respiratory depression; hepatotoxicity with chronic high doses; GI bleeding, ulceration, and perforation with aspirin; renal toxicity; hypersensitivity reactions; use in elderly, renal/hepatic impairment, or history of alcohol abuse.
Hypersensitivity to propoxyphene, aspirin, or NSAIDs; severe respiratory depression; acute or severe asthma; GI bleeding; history of peptic ulcer disease; hemophilia; children with viral infections (Reye's syndrome); concurrent MAOIs or alcohol.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but not clinically significant.
Avoid alcohol. Aspirin component may cause gastrointestinal irritation; take with food or milk to reduce stomach upset. Avoid foods high in tyramine (e.g., aged cheese, processed meats) as propoxyphene may have weak MAOI activity? Not established but caution advised.
Propoxyphene is excreted into breast milk in low concentrations (M/P ratio approximately 0.5); however, the combination with acetaminophen may pose risks of sedation and respiratory depression in the infant. Acetaminophen is considered compatible with breastfeeding. Use with caution, monitor infant for drowsiness and feeding difficulties.
Aspirin enters breast milk in low amounts; M/P ratio ~0.1. Propoxyphene M/P ratio ~0.5. Both can accumulate in neonates with repeated dosing. Potential for infant sedation, respiratory depression, and Reye's syndrome. Contraindicated in breastfeeding due to risks.
No specific dosing adjustments for propoxyphene/acetaminophen in pregnancy are established. However, pregnancy can alter propoxyphene pharmacokinetics (e.g., increased clearance, volume of distribution); thus, doses may need adjustment based on clinical response and toxicity monitoring. Generally, lowest effective dose for shortest duration is recommended.
No specific dose adjustments in pregnancy. However, because of altered pharmacokinetics (increased volume of distribution, renal clearance), clinicians should titrate to effect and monitor for toxicity. Avoid high-dose aspirin in third trimester due to fetal risks. Propoxyphene clearance may be increased in pregnancy, but no standard dose change recommended; use minimal effective dose.
Do not exceed recommended dose; acetaminophen overdose can cause severe liver damage.,Propoxyphene may cause dizziness, drowsiness, or confusion; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants during therapy.,Inform your doctor if you have a history of heart rhythm problems, as propoxyphene can affect heart rhythm.,Do not stop abruptly after prolonged use; withdrawal may occur.
Do not take more than prescribed as overdose can cause serious heart problems or death.,Avoid alcohol while taking this medication as it increases risk of liver damage and bleeding.,Aspirin may increase risk of bleeding; report unusual bruising or bleeding to your doctor.,If you have asthma, nasal polyps, or allergies, aspirin may cause severe allergic reactions.,Do not use in children or teenagers with chickenpox or flu-like symptoms due to risk of Reye's syndrome.,This medicine may cause drowsiness or dizziness; avoid driving until you know how it affects you.